-
公开(公告)号：US09446032B2
公开(公告)日：2016-09-20
申请号：US14240380
申请日：2012-08-23
IPC分类号： A61K9/22 , A61K31/4418 , A61K31/138 , A61K31/40 , A61K31/41 , A61K45/06
CPC分类号： A61K31/4418 , A61K31/138 , A61K31/40 , A61K31/41 , A61K45/06 , A61K31/135 , A61K2300/00 , A61K31/4422
摘要： There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient.
摘要翻译： 提供了用于治疗心血管疾病的每日一次治疗协同药物剂型，其中剂型包括延长释放形式的美托洛尔和一种或多种钙通道阻滞剂，血管紧张素II受体阻断剂或血管紧张素转化酶的固定剂量组合 酶抑制剂以及一种或多种速率控制赋形剂。
-
公开(公告)号：US20140302125A1
公开(公告)日：2014-10-09
申请号：US14240380
申请日：2012-08-23
IPC分类号： A61K31/4418 , A61K31/41 , A61K31/40 , A61K31/138
CPC分类号： A61K31/4418 , A61K31/138 , A61K31/40 , A61K31/41 , A61K45/06 , A61K31/135 , A61K2300/00 , A61K31/4422
摘要： There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient.
摘要翻译： 提供了用于治疗心血管疾病的每日一次治疗协同药物剂型，其中剂型包括延长释放形式的美托洛尔和一种或多种钙通道阻滞剂，血管紧张素II受体阻断剂或血管紧张素转化酶的固定剂量组合 酶抑制剂以及一种或多种速率控制赋形剂。
-
3.发明授权公开(公告)号：US09408814B2
公开(公告)日：2016-08-09
申请号：US13582440
申请日：2011-03-21
IPC分类号： A61K31/137 , A61P15/00 , A61P25/00 , A61P25/08 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P3/04 , A61K9/20 , A61K9/28 , A61K47/24
CPC分类号： A61K31/137 , A61K9/2054 , A61K9/2866 , A61K47/24
摘要： The present invention refers to a modified release pharmaceutical composition comprising desvenlafaxine or salts thereof, a release rate modifying system that controls the release of active agent(s) in both acidic and basic environments. A process of making and method of using the above-described composition is also disclosed.
摘要翻译： 本发明涉及包含去甲文拉法辛或其盐的释放药物组合物，其控制在酸性和碱性环境中释放活性剂的释放速率改变系统。 还公开了制备方法和使用上述组合物的方法。
-
4.发明申请公开(公告)号：US20130059917A1
公开(公告)日：2013-03-07
申请号：US13582440
申请日：2011-03-21
IPC分类号： A61K31/137 , A61P25/24 , A61P25/22 , A61P25/08 , A61P25/18 , A61P15/00 , A61P25/16 , A61P25/00 , A61P3/04
CPC分类号： A61K31/137 , A61K9/2054 , A61K9/2866 , A61K47/24
摘要： The present invention refers to a modified release pharmaceutical composition comprising desvenlafaxine or salts thereof, a release rate modifying system that controls the release of active agent(s) in both acidic and basic environments. A process of making and method of using the above-described composition is also disclosed.
摘要翻译： 本发明涉及包含去甲文拉法辛或其盐的释放药物组合物，其控制在酸性和碱性环境中释放活性剂的释放速率改变系统。 还公开了制备方法和使用上述组合物的方法。
-
公开(公告)号：US20090275552A1
公开(公告)日：2009-11-05
申请号：US12226525
申请日：2007-04-27
申请人： Mahesh Vithalbhai Patel , Shrikant Vinayak Gupte , Sachin Subhash Bhagwat , Mohammad Alam Jafri , Girish Kumar Jain , Mandar Madhukar Kodgule
发明人： Mahesh Vithalbhai Patel , Shrikant Vinayak Gupte , Sachin Subhash Bhagwat , Mohammad Alam Jafri , Girish Kumar Jain , Mandar Madhukar Kodgule
IPC分类号： A61K31/397
CPC分类号： A61K31/43 , A61K9/0019 , A61K9/0095 , A61K9/1652 , A61K9/2054 , A61K31/546 , A61K2300/00
摘要： The invention relates to an improved therapy for treating resistant bacterial infections caused by extended-spectrum β-lactamase (ESBLs)-producing strains in a warm-blooded animal, adjuvant step down therapy, and pharmaceutical compositions for such therapies. The invention also relates to a method for inhibiting bacterial resistance in ESBLs-producing strains so as to have better control over the therapy; achieve reduced hospital stay and adjuvant step down therapy so as to avoid recrudescence. In particular, the therapy includes antibacterial combination of cefepime with sulbactam via parenteral route, followed by oral third generation cephalosporin with a suitable β lactamase inhibitor.
摘要翻译： 本发明涉及用于治疗由温血动物中的扩展型β-内酰胺酶（ESBL））产生菌株引起的抗性细菌感染的改进疗法，佐剂降解疗法和用于此类疗法的药物组合物。 本发明还涉及一种抑制ESBLs产生菌株细菌耐药性的方法，以便更好地控制治疗; 实现减少住院时间和辅助降压治疗，避免复发。 特别地，该疗法包括通过肠胃外途径将头孢吡肟与舒巴坦的抗菌结合，随后用合适的β-内酰胺酶抑制剂口服第三代头孢菌素。
-
公开(公告)号：US08449912B2
公开(公告)日：2013-05-28
申请号：US13475968
申请日：2012-05-19
IPC分类号： A61K9/24
CPC分类号： A61K9/209 , A61K31/517
摘要： The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers.
-
公开(公告)号：US08206742B2
公开(公告)日：2012-06-26
申请号：US11991369
申请日：2007-01-12
IPC分类号： A61K9/24
CPC分类号： A61K9/209 , A61K31/517
摘要： The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers.
摘要翻译： 本发明涉及包含一个或多个功能层的阿夫唑嗪或其药学上可接受的盐的持续释放组合物。 功能层包括阿夫唑嗪或其药学上可接受的盐和一种或多种药学上可接受的亲水和/或疏水速率控制聚合物。
-
公开(公告)号：US08454999B2
公开(公告)日：2013-06-04
申请号：US13475983
申请日：2012-05-19
IPC分类号： A61K9/24
CPC分类号： A61K9/209 , A61K31/517
摘要： The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers.
-
公开(公告)号：US20090028942A1
公开(公告)日：2009-01-29
申请号：US11991369
申请日：2007-01-12
IPC分类号： A61K31/517
CPC分类号： A61K9/209 , A61K31/517
摘要： The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers.
摘要翻译： 本发明涉及包含一个或多个功能层的阿夫唑嗪或其药学上可接受的盐的持续释放组合物。 功能层包括阿夫唑嗪或其药学上可接受的盐和一种或多种药学上可接受的亲水和/或疏水速率控制聚合物。
-
公开(公告)号：US10292994B2
公开(公告)日：2019-05-21
申请号：US14113561
申请日：2012-04-25
申请人： Rakesh Maurya , Preety Dixit , Ritu Trivedi , Vikram Khedgikar , Jyoti Gautam , Avinash Kumar , Divya Singh , Shelendra Pratap Singh , Wahajuddin , Girish Kumar Jain , Naibedya Chattopadhyay
发明人： Rakesh Maurya , Preety Dixit , Ritu Trivedi , Vikram Khedgikar , Jyoti Gautam , Avinash Kumar , Divya Singh , Shelendra Pratap Singh , Wahajuddin , Girish Kumar Jain , Naibedya Chattopadhyay
IPC分类号： A61K31/7048 , C07D311/36 , C07H17/07 , A61K31/352 , A61K36/48
摘要： The present invention relates to bioactive fractions and compounds from Dalbergia sissoo for the prevention or treatment of osteo-health related disorders. The present invention relates in the field of pharmaceutical composition that provides new plant extracts, their fractions and pure compound isolated from natural sources that are useful for the prevention and/or treatment of various medical indications associated with estrogen dependent or independent diseases or syndromes or disorders preferably in the prevention or treatment of estrogen dependent or independent diseases or syndromes or disorders caused in humans and animals, and achievement of peak bone mass during skeletal growth and health in humans and animals. Particularly the present invention further relates to the processes for the preparation of biologically active extracts, fractions, and isolation of pure compounds, from Dalbergia sissoo plant from the family Fabaceae their pharmaceutically acceptable salts and compositions of the principal aspect of the present invention.
-
-
-
-
-
-
-
-
-
搜索结果
64 条记录 (耗时 0.029 秒)
